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Introduction
Abnormal activation of the Ras signaling pathway is commonly found in human tumors. Oncogenic mutations 
in Ras family proteins, such as K-RasG12D, constitutively activate growth factor signaling pathways and drive 
uncontrolled cell growth, proliferation, and invasiveness (1–3). Mutations in K-Ras occur in 33% of human 
lung adenocarcinomas (LADCs) (4), and mutation of K-Ras in the mouse lung is sufficient to induce LADC 
formation (5). However, since direct targeting of oncogenic Ras has proved extremely challenging, a detailed 
understanding of Ras downstream pathways is critical to enable targeted therapy for Ras-driven tumors. This 
need is especially pressing for lung cancer, a tumor type that often responds poorly to current treatments (6).
Among its many outputs, oncogenic Ras signaling stimulates the AP-1 transcriptional activator family, 
which in turn controls a vast suite of  genes involved in proliferation, migration, and apoptosis (7–9). AP-1 
family transcription factors are dimeric complexes, composed of  various Fos and Jun proteins, which bind 
a common consensus site known as the TPA response element. The 3 Jun proteins — c-Jun, JunD, and 
JunB — can either heterodimerize or homodimerize to form an AP-1 complex, and each shows subtle 
but important differences in regulation and output. JunD- and c-Jun–containing transcription factors are 
thought to control different, though overlapping, sets of  AP-1 target genes (10). In certain contexts, Jun 
proteins appear to have opposite functions: for example, in immortalized mouse embryonic fibroblasts 
(MEFs), c-Jun promotes cell proliferation but JunD inhibits it (11, 12). However, each Jun protein can also 
influence cell behavior in very different ways depending on context — for example, by promoting apoptosis 
in response to cellular stress or proliferation in response to growth factors (7–9).
Since its discovery as the cellular counterpart of  a viral oncoprotein, c-Jun has had a well-established 
role in tumorigenesis. c-Jun–/– MEFs display severe proliferation defects and deficiency in cell cycle reentry 
after serum withdrawal (9, 11, 13). As well as its effects on proliferation through transcriptional upregulation 
of  cell cycle genes such as cyclinD1 and cdc2 (9, 14–16), studies in cultured cells demonstrated that c-Jun is 
The AP-1 transcription factor c-Jun is required for Ras-driven tumorigenesis in many tissues 
and is considered as a classical proto-oncogene. To determine the requirement for c-Jun in a 
mouse model of K-RasG12D–induced lung adenocarcinoma, we inducibly deleted c-Jun in the adult 
lung. Surprisingly, we found that inactivation of c-Jun, or mutation of its JNK phosphorylation 
sites, actually increased lung tumor burden. Mechanistically, we found that protein levels of the 
Jun family member JunD were increased in the absence of c-Jun. In c-Jun–deficient cells, JunD 
phosphorylation was increased, and expression of a dominant-active JNKK2-JNK1 transgene further 
increased lung tumor formation. Strikingly, deletion of JunD completely abolished Ras-driven lung 
tumorigenesis. This work identifies JunD, not c-Jun, as the crucial substrate of JNK signaling and 
oncogene required for Ras-induced lung cancer.
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required for Ras-mediated oncogenic transformation (17, 18). Conversely, whereas c-Jun cooperates with 
oncogenic Ras, JunD partially suppresses transformation by activated Ras (19). c-Jun family proteins are 
activated by phosphorylation mediated by the Jun N-terminal kinases (JNKs) (20). JNK phosphorylates 
c-Jun on 4 sites — serine 63 (Ser63), Ser73, Ser91, and Ser93 — and JunD on Ser90, Ser100, and Ser117 
(21). A mutant allele of  c-Jun, in which the JNK phosphoacceptor Ser63 and Ser73 are changed to alanines 
(JunAA), reduced both oncogenic transformation caused by constitutive activation of  the Ras pathway in 
immortalized fibroblasts and skin tumor development (22), indicating a protumorigenic role of  c-Jun N-ter-
minal phosphorylation in Ras-induced transformation. However, the contribution of  JunD phosphorylation 
in the context of  oncogenic Ras has not been investigated.
The importance of AP-1 transcription as an output of Ras signaling suggested that c-Jun could be crucial 
for other tumor types, particularly those driven by oncogenic Ras. Indeed, recent work from our laboratory 
found that overexpression of the AP-1 coactivator RACO-1 cooperates with oncogenic Ras to increase tumor 
burden in a mouse model of lung cancer (23, 24). However, the role of c-Jun in lung tumorigenesis was unclear.
In this study, we investigated the importance of  different AP-1 components in lung tumorigenesis, using 
lung-specific deletion of  c-Jun or JunD combined with the inducible K-Ras–driven model of  LADC (5, 25). 
Unexpectedly, we found that c-Jun acts as a tumor suppressor in the lung, while JunD is crucial for Ras-driv-
en lung tumor formation. Importantly, JNK signaling appears to be critical in these tumors, as shown by the 
increased tumor burden observed in a transgenic model of  JNK activation and the heightened sensitivity 
of  c-Jun–null lung tumor cells to JNK inhibitors. These data suggest that, in complete contrast to previous 
findings in other tumor types, c-Jun has tumor-suppressive function in Ras-induced lung tumorigenesis, but 
paradoxically, JNK should be considered as a therapeutic target in LADC.
Results
JUN is frequently lost in human LADC patients. To evaluate a potential role for genetic disruption of  JUN in 
human LADC, we analyzed The Cancer Genome Atlas (TCGA) data from 230 LADC cases. Interestingly, 
up to 26% of  human LADC cases showed loss-of-function genetic alterations (Figure 1A). Moreover, JUN 
and KRAS genetic alterations occurred together in a subset of  human LADC patients (P = 0.028) (Figure 
1A). We also examined the correlation between JUN expression level and LADC patient survival. Inter-
estingly, lower expression of  JUN was associated with a significantly shorter survival time (P = 1.9 × 10–7) 
(Figure 1B). Altogether, these data suggest that JUN is often downregulated in human LADC and occurs 
together with KRAS genetic alterations. Therefore, we investigated the functional role of  JUN in lung cancer.
c-Jun is tumor suppressive in the K-RasG12D LADC model. To determine the role of c-Jun in Ras-driven lung 
tumorigenesis, we generated mice harboring c-Junfl/fl and lsl-K-RasG12D alleles and induced c-Jun deletion and 
K-RasG12D expression in the lung by intratracheal delivery of adenoviral Cre recombinase (Figure 1C) (25). 
When analyzed after 12 weeks, both c-Junfl/fl; lsl-K-RasG12D mice and lsl-K-RasG12D controls had developed multiple 
lung tumors that stained positive for thyroid transcription factor 1 (TTF-1), identifying them as adenocarcino-
mas (Figure 1D and Supplemental Figure 1A; supplemental material available online with this article; https://
doi.org/10.1172/jci.insight.124985DS1). Surprisingly, in c-Jun–deleted lungs, tumor burden was significantly 
increased and tumors were more proliferative as measured by Ki67 staining (Figure 1, D–F, and Supplemental 
Figure 1B). The average tumor grade was also increased, with c-Junfl/fl; lsl-K-RasG12D animals exhibiting grade 4 
LADCs, which were HMGA2+/TTF-1– and not observed in controls (Supplemental Figure 1, C and D), and 
some additionally showing lepidic predominant adenocarcinoma (formerly BAC) lesions (Supplemental Figure 
1E). To confirm that c-Jun was not active in the observed tumors, we performed IHC staining for c-Jun activat-
ing phosphorylation at Ser63 and Ser73 (Figure 1G). Consistent with c-Jun deletion, c-Jun and phospho-Ser63 
staining was undetectable in lung tumors from c-Junfl/fl; lsl-K-RasG12D animals. However, the antibody detecting 
c-Jun phospho-Ser73, which also recognizes JunD phospho-Ser100, showed increased staining in these tumors. 
c-Jun–null tumors showed increased staining for JunD (Figure 1G). Thus, in complete contrast to the previously 
described roles of c-Jun as oncogene and JunD as tumor suppressor (8), Ras-driven lung tumors increase in the 
absence of c-Jun and show increased JunD phosphorylation and protein expression (Figure 1H).
JunD phosphorylation is increased in c-Jun–null cells. To investigate the potential oncogenic changes caused 
by c-Jun deletion in K-Ras mutant lung cells, we isolated primary tumor cells for biochemical analysis. 
Despite their vigorous growth in vivo, primary tumor cells could not be established from c-Junfl/fl; lsl-K-RasG12D 
mice. The severe proliferation defect of  c-Jun–deficient primary fibroblasts is rescued by concomitant Tp53 
(p53) inactivation (11). Thus, to enable the establishment of  primary tumor cell lines in vitro, we combined 
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c-Junfl/fl; lsl-K-RasG12D alleles with p53 deletion (Figure 2A). KRAS and TP53 are the most commonly mutated 
genes in human LADC (4), recapitulated by the widely used lsl-K-RasG12D; p53fl/fl (KP) mouse model. As in 
the p53 WT model, c-Junfl/fl; lsl-K-RasG12D; p53fl/fl (JKP) mice developed LADCs negative for c-Jun and positive 
for phospho-JunD (Ser100) (Figure 2B). Tumor area and cell proliferation were significantly increased in 
JKP compared with KP mice (Figure 2, C and D, and Supplemental Figure 2A). After isolating individual 
lung tumors, KP and JKP cell lines could be established (Figure 2E). We analyzed c-Jun and JunD iso-
forms that share JNK phosphoacceptor residues recognized by the phospho-Jun (Ser73/Ser100) antibody. 
Immunoblotting experiments showed that both JunD protein expression and JunD Ser100 phosphorylation 
rose as a consequence of  c-Jun deletion (Figure 2, F and G). Importantly, expression analysis on primary 
human LADC biopsy samples showed simultaneous downregulation of  JUN and upregulation of  JUND 
(Figure 2H). Moreover, KP and JKP cells retained their tumorigenicity in culture, as shown by orthotopic 
transplant of  cultured cells directly to the lungs of  Nu/Nu mice by intratracheal delivery or s.c. tumor grafts 
(Supplemental Figure 2, B–F). As expected, tumors derived from JKP cells showed increased levels of  JunD 
protein alongside loss of  c-Jun immunostaining (Supplemental Figure 2E), and JKP tumor–bearing mice 
succumbed earlier than KP mice (Supplemental Figure 2G). Thus, loss of  c-Jun expression was associated 
with a significantly shorter survival time.
c-Jun–deficient cells are more sensitive to JNK inhibition. To examine the effects of  JNK on c-Jun and JunD in 
lung tumors, we treated KP and JKP cells with anisomycin to activate JNK, and we analyzed phosphorylation 
of  c-Jun at Ser63 and Ser73, and phosphorylation of  JunD at the analogous Ser100. To be able to distinguish 
phosphorylation of  c-Jun and JunD separately, we ran large gels and separate bands representing c-Jun, and 
the long and short isoforms of  JunD were clearly visible. As expected, anisomycin treatment increased phos-
phorylation of  c-Jun Ser63, as well as increasing total levels of  c-Jun in KP cells (Figure 2I). JNK-mediated 
phosphorylation of  JunD at Ser100 was more efficient than phospho–c-Jun Ser73 in KP cells (Figure 2I and 
Supplemental Figure 2H). In JKP cells, JunD protein and JunD phosphorylation levels were significantly 
increased, and anisomycin further stimulated phospho–JunD Ser100. Because the total observed phosphor-
ylation detected by the c-Jun Ser73/JunD Ser100 antibody is exclusively due to JunD in JKP cells, this result 
indicates a greater increase in JunD Ser100 phosphorylation in the absence of  c-Jun (Figure 2I). Moreover, 
the increased phospho–JunD Ser100 in anisomycin-stimulated JKP compared with KP cells was JNK depen-
dent (Figure 2I and Supplemental Figure 2H). This suggests that, in the absence of  c-Jun, JNK stimulation of  
JunD is increased. To test the dependence of  JKP cells on JNK, we measured the proliferation of  primary KP 
and JKP cells in the absence or presence of  the JNK inhibitor SP600125. In support of  an increased role for 
JNK in supporting proliferation in the absence of  c-Jun, JKP cells were more sensitive to JNK inhibition than 
KP cells (Figure 2J). Thus, JNK signaling appears to be critical in c-Jun–null lung tumor cells.
c-JunAA increases lung tumor burden, phenocopying c-Jun deletion. To test the idea that JNK-mediated phos-
phorylation is important for tumorigenesis, we used the partially inactive c-Jun S63A, S73A N-terminal 
phosphorylation mutant, termed c-JunAA. This mutant lacks 2 JNK phosphorylation sites and shows 
impaired, but not abolished, AP-1 transactivation (26). We generated c-JunAA/AA; lsl-K-RasG12D mice and 
induced tumorigenesis by administration of  adenoviral Cre to the lung, as before (Figure 3A). The presence 
of  mutant c-Jun did not impair tumorigenesis; in fact, lung tumor burden and cell proliferation in tumors 
were increased, as in the c-Jun deletion model (Figure 3, B–D). Thus, despite the presence of  c-Jun protein, 
as detected by IHC (Figure 3E), impaired JNK phosphorylation of  c-Jun was sufficient to increase Ras-driv-
en lung tumorigenesis (Figure 3F). Interestingly, JunD levels were also increased in c-JunAA/AA; lsl-K-RasG12D 
mice, similar to the c-Jun deletion model (Figure 3E). As JunAA still binds and induces its target promoters 
Figure 1. c-Jun is tumor suppressive in the KRasG12D lung adenocarcinoma model. (A) Genetic alterations in JUN and KRAS genes in human LADC. Each 
column represents a tumor sample (n = 230). Data from TCGA were analyzed using cBioportal software. (B) Kaplan-Meier plot showing the association between 
JUN expression and patient survival. Analysis performed using KM plotter lung cancer database (cut-off median). (C) Schematic representation of c-Junfl/fl; 
lsl-KRasG12D mouse model. Conditional c-Jun deletion and K-RasG12D expression in the lung was induced by intratracheal intubation (i.t.) with adenovirus carrying 
Cre recombinase (Adeno-Cre). LoxP (locus of recombination) sites are indicated by black triangles. LSL, stop cassette flanked by 2 loxP sites. (D) H&E and TTF-1 
antibody stains of lung sections from mice of the indicated genotypes, 12 weeks after intubation. Scale bars: 2 mm (whole sections), 50 μm (magnified tumor 
areas). (E) Quantification of the tumor burden in whole lungs isolated from K-RasG12D (4 mice/20 lobes) and c-JunΔ/Δ; K-RasG12D (3 mice/14 lobes) mice. Dots, indi-
vidual lobes; red horizontal line, median. P values calculated using unpaired t test with Welch’s correction. (F) Violin plots quantifying the percentage of Ki67+ 
cells in lung tumors from mice of the indicated genotypes. K-RasG12D (4 mice/36 tumors) and c-JunΔ/Δ; K-RasG12D (3 mice/48 tumors). Each data point represents 
one tumor. Red horizontal line, median. P values calculated using unpaired t test with Welch’s correction. (G) c-Jun, phospho–c-JunSer63, phospho–c-JunSer73/
phospho-JunDSer100, and JunD antibody stains of lung tumors from mice of the indicated genotypes. Scale bars: 50 μm, 5 μm (inset). (H) Schematic summary: 
c-Jun is tumor-suppressor (left). In the absence of c-Jun, K-Ras–dependent tumors increase, possibly through activation of JunD (right). JunDP, phospho-JunD.
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(26), the observed c-Jun–null–like (c-JunΔL–like) phenotype observed in c-JunAA/AA; lsl-K-RasG12D mice suggests 
an essential role for JNK signaling.
JNK activity is protumorigenic in the absence of  c-Jun. To test JNK activity in vivo, we combined induc-
ible K-RasG12D expression and c-Jun deletion in the lung with a conditional JNKK2-JNK1 transgene to aug-
ment JNK activity (Figure 4A and Supplemental Figure 3, A–D). Expression of  the transgene increased 
K-RasG12D–driven tumor burden and tumor cell proliferation, suggesting that JNK activity is protumorigenic 
(Figure 4, B–D, and Supplemental Figure 3E). Tumor burden was significantly (P = 4.5 × 10–4) increased in 
the lungs of  c-Junfl/fl; lsl-Jnkk2-Jnk1; lsl-K-RasG12D mice compared with c-Junfl/fl; lsl-K-RasG12D mice, suggesting 
that c-Jun loss and increased JNK activity cooperate to promote tumorigenesis (Figure 4B and Supplemental 
Figure 3F). Consistent with JunD as a key effector of  JNK, JunD levels were increased in correlation with 
the increased tumor burden in c-Junfl/fl; lsl-Jnkk2-Jnk1; lsl-K-RasG12D lungs, with positive staining for phos-
pho-JunD Ser100 (Figure 4E). Thus, although c-Jun is tumor suppressive in the context of  Ras-driven lung 
tumorigenesis, JNK signaling appears to be oncogenic, and increased JunD phosphorylation by JNK is a 
potent tumor promoter in the lung (Figure 4F).
JunD is required for Ras-driven lung tumorigenesis. To investigate the correlation between JUND levels and 
patient survival, we examined JUND expression from a transcriptomic data set of  a human LADC cohort. 
We found that high JUND expression is significantly correlated with decreased overall survival for patients 
with LADC (P = 3.3 × 10–4) (Supplemental Figure 4A).
To directly test the role of  JunD in Ras-driven lung tumorigenesis, we combined inducible K-RasG12D 
expression in the lung with JunD germline KO (Figure 5A). Strikingly, K-RasG12D was unable to induce 
lung tumors in JunD–/– mice, and cell proliferation in lungs was correspondingly reduced (Figure 5, B–D, 
and Supplemental Figure 4B). Since JunD–/– animals show postnatal growth defects, we also examined 
JunD heterozygotes, which are indistinguishable in size from WT littermates (27). JunD heterozygous 
mice expressing K-RasG12D in the lung also showed a significantly reduced tumor burden compared with 
JunD-proficient controls (Figure 5C), suggesting that JunD plays a driving role in K-RasG12D–induced tum-
origenesis. We confirmed loss of  JunD and expression of  the LacZ knockin by IHC (Figure 5E).
As JunD was knocked out throughout the whole mouse, there was the possibility that nontumor cells 
may have played a role during tumorigenesis. Thus, to confirm a function of  JunD in lung cancer cells, 
JunD protein expression was knocked out via CRISPR/Cas9 in primary lung KP cells. JunD-null cells 
(KPD) proliferated slower than parental KP controls (Supplemental Figure 4C). When injected s.c. into 
nude mice, JunD-deficient cells formed graft tumors that were smaller and grew slower than those derived 
from KP cells (Supplemental Figure 4, D and E). Importantly, JUND downregulation by siRNA severely 
reduced cell proliferation in human LADC cell lines (Figure 5F and Supplemental Figure 5, A and B). The 
loss of  cell growth was associated with apoptotic cell death, as detected by caspase-3 activity probes (Figure 
5G and Supplemental Figure 5C). Thus, these data suggest a role for JunD in lung tumorigenesis.
We next performed immunoblotting analysis for Jun protein levels and activating phosphorylation at c-Jun 
Ser63 and c-Jun Ser73/JunD Ser100. Surprisingly, c-Jun protein levels, phospho–c-Jun Ser63, and phospho–c-
Jun Ser73 levels were significantly reduced in both mouse and human JunD–deficient cells (Supplemental Fig-
ure 4, F and G, and Supplemental Figure 5B). IHC analysis in JunD–/–; lsl-K-RasG12D lungs confirmed reduction 
in phospho–c-Jun Ser63 and phospho–c-Jun Ser73 (Figure 5E). Importantly, immunoblotting experiments did 
not show any alteration in JNK protein and active JNK phospho-JNKThr183/Tyr185 levels in JunD-deficient cells 
(Supplemental Figure 4, F and G). These results suggest that JNK activity is unaltered in JunD-KO cells.
Figure 2. JunD phosphorylation is increased in c-Jun–null cells, which are more sensitive to JNK inhibition. (A) Schematic representation of c-Junfl/fl; lsl-KRasG12D; 
p53fl/fl mouse model. Conditional c-Jun and p53 deletions and K-RasG12D expression in the lung was induced by intratracheal intubation (i.t.) with adenovirus carry-
ing Cre recombinase (Adeno-Cre). (B) H&E, c-Jun, and phospho–c-JunSer73/phospho-JunDSer100 stains of lung tumors from mice of the indicated genotypes, 10 
weeks after intubation. Scale bars: 2 mm (whole sections), 5 μm (inset). (C) Quantification of the tumor burden in whole lungs isolated from KP (3 mice/14 lobes) 
and JKP (3 mice/15 lobes) mice. Dots, individual lobes; red horizontal line, median. P values calculated using unpaired t test with Welch’s correction. (D) Violin plots 
quantifying the percentage of Ki67+ cells in lung tumors from mice of the indicated genotypes. KP (3 mice/60 tumors) and JKP (3 mice/85 tumors). Dots, individual 
lobes; red horizontal line, median. P values calculated using unpaired t test with Welch’s correction. (E) Lung tumor cells from KP and JKP mice were isolated 
and cultured in vitro. (F and G) Immunoblot analysis (F) and quantification (G) of KP and JKP cells probed for phospho–c-JunSer73/phospho-JunDSer100, JunD, 
and c-Jun. The results are expressed as mean ± SEM (n = 3 per group). Unpaired t test with Welch’s correction. (H) Relative mRNA expression of JUN and JUND in 
normal lung tissue (n = 5) and LADC (n = 9) patient samples measured by RT-PCR. Comparison of JUN and JUND mRNA expression between matched LADC patient 
samples. (I) Immunoblot analysis of KP and JKP cells with and without anisomycin and JNK inhibitor (SP600125) treatments. (J) KP and JKP cells were cultured 
with and without JNK inhibitor (SP600125), and proliferation was measured by counting the number of cells. Graph shows means ± SD; ****P < 0.0001, P values 
calculated using 2-way ANOVA with Tukey’s multiple-comparison test.
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As lung tumorigenesis appears to be JunD dependant, we performed RNA-sequencing (RNA-Seq) 
experiments using primary KP and JKP tumor cells to gain mechanistic insights. Gene set enrichment 
analysis (GSEA) found that oxidative stress, adipogenesis, and p38 MAPK pathways were upregulated 
in JKP cells (Supplemental Figure 6A), where JunD phosphorylation and protein expression were 
Figure 3. c-JunAA increases lung tumor burden, phenocopying c-Jun deletion. (A) Schematic representation of c-JunAA/AA; lsl-KRasG12D mouse model. The 
c-JunAA allele lacks the JNK phosphorylation sites Ser63 and Ser73. Expression of K-RasG12D was induced by intratracheal intubation (i.t.) with adenovirus 
carrying Cre recombinase (Adeno-Cre). LSL, stop cassette flanked by 2 loxP (locus of recombination) sites. (B) H&E and TTF-1 antibody stains of lung sections 
from mice of the indicated genotypes, 12 weeks after intubation. Scale bars: 2 mm (whole sections), 50 μm (magnified areas). (C) Quantification of the tumor 
burden in whole lungs isolated from K-RasG12D (4 mice/18 lobes) and c-JunAA/AA; K-RasG12D (3 mice/15 lobes) mice. Dots, individual lobes; red horizontal line, 
median. P values calculated using unpaired t test with Welch’s correction. (D) Violin plots quantifying the percentage of Ki67+ cells in lung tumors from mice 
of the indicated genotypes. K-RasG12D (3 mice/35 tumors) and c-JunAA/AA; K-RasG12D (3 mice/80 tumors). Each data point represents 1 tumor. Red horizontal line, 
median. P values calculated using unpaired t test with Welch’s correction. (E) c-Jun, phospho–c-JunSer63, phospho–c-JunSer73/phospho-JunDSer100, and JunD 
antibody stains of lung tumors from mice of the indicated genotypes. Scale bars: 50 μm, 5 μm (inset). (F) Schematic summary: Blocking JNK phosphorylation 
of c-Jun increases oncogenic K-Ras–dependent lung tumor burden, similar to the effects of c-Jun deletion, possibly via increased phosphorylation of JunD.
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increased (Figure 2F). These data are in agreement with a previous study that indicated JunD works as 
an activator of  transcription of  genes involved in oxidative stress, differentiation, and cell proliferation 
(28). We further confirmed activation of  p38α MAPK in JKP cells (Supplemental Figure 6B), which 
correlated with increased JunD protein levels (Supplemental Figure 6C). Therefore, JKP cells were 
sensitive to p38 MAPK inhibition (Supplemental Figure 6D). By contrast, p38α MAPK activation was 
reduced in JunD-deficient cells (Supplemental Figure 6C). In addition, analysis of  public gene expres-
sion databases revealed a positive correlation between the expression of  JUND and MAPK14 in human 
LADC samples (Supplemental Figure 6E). Interestingly, p38α protein and phosphorylation levels are 
increased and correlate with poor survival in LADC patients (29, 30). Moreover, p38α supports the 
progression of  K-Ras–driven lung tumors (30). Thus, p38α MAPK pathway activation could contrib-
ute to the effects of  JunD as a lung tumor promoter.
Overall, these results support a tumor-suppressive role for c-Jun in the lung and demonstrate that JunD 
is required for Ras-driven lung tumorigenesis.
Discussion
Unexpectedly, we found that c-Jun, a classic proto-oncogene, has a tumor-suppressive effect in a well-estab-
lished model of  LADC. These results are surprising, since c-Jun was shown to cooperate with oncogenic 
K-Ras in promoting proliferation of  cultured fibroblasts, and because of  the requirement for c-Jun in skin, 
liver, and intestinal Ras-dependent tumor models (17, 18, 22, 31, 32).
Instead, our results shown that JunD is essential for lung tumorigenesis. It is tempting to speculate 
that JNK signaling has tumor-suppressive effects through c-Jun and tumor-promoting effects through 
JunD and that loss of  one arm tips the balance toward the effects of  the other arm. To investigate the 
possibility that increased JunD function underlies the increased lung tumorigenesis in the absence of  
c-jun, we aimed to knock out JunD in JKP cells through CRISPR-meditated genome editing. Unfor-
tunately, c-Jun/JunD–double KO cell lines could not be generated, possibly because JunD function is 
essential in JKP cells (data not shown). However, we successfully derived KP cells deficient in JunD 
through CRISPR, and these cells showed a clear growth disadvantage.
Our results show that c-Jun protein and phosphorylation levels are reduced in the absence of  JunD. 
By contrast, JunD protein and phosphorylation levels rise in the absence of  c-Jun. JNK signaling was 
shown to have tumor-promoting and tumor-suppressive functions in tumorigenesis. A previous study 
found that JNK is essential for Ras-driven lung tumorigenesis, but the relevant JNK substrates were 
not identified (33). In other systems, such as prostate and breast cancers, JNK has been shown to be 
tumor suppressive (34, 35), while in the liver, JNK has both pro- and antitumorigenic roles (36). It is 
possible that the balance between c-Jun and JunD contributes to the variation in JNK signaling out-
come in these different contexts. Our data suggest that JNK activity is protumorigenic in absence of  
c-Jun through JunD. JunD is phosphorylated by ERK, as well as JNK (37), so ERK-driven function 
may contribute to JunD’s role in K-Ras–driven tumors. Indeed, JunD increases prostate cancer cell 
migration in an ERK-dependent manner (10). We also do not discard the possibility that c-Jun loss 
and/or JNK activation additionally promote tumorigenesis by JunD-independent mechanisms. How-
ever, our in vivo data indicate that JunD is absolutely required for K-Ras–driven lung tumorigenesis, 
highlighting JunD as an important protumorigenic JNK target.
Figure 4. JNK activity is protumorigenic in the absence of c-Jun. (A) Schematic representation of c-Junfl/fl; lsl-Jnkk2-Jnk1; lsl-K-RasG12D mouse model. 
Conditional c-Jun deletion and expression of K-RasG12D and the Jnkk2-Jnk1 transgene (described in Supplemental Figure 3) in the lung was induced by intra-
tracheal intubation (i.t.) with adenovirus carrying Cre recombinase (Adeno-Cre). LSL, stop cassette flanked by 2 loxP (locus of recombination) sites (black 
triangles); IRES, internal ribosome entry site. (B) H&E and TTF-1 antibody stains of lung sections from mice of the indicated genotypes, 12 weeks after 
intubation. Scale bars: 2 mm (whole sections), 50 μm (magnified areas). (C) Quantification of the tumor burden in whole lungs isolated from K-RasG12D (4 
mice/20 lobes), c-JunΔ/Δ; K-RasG12D (3 mice/15 lobes), Jnkk2-Jnk1; K-RasG12D (3 mice/14 lobes), and c-JunΔ/Δ; Jnkk2-Jnk1; K-RasG12D (4 mice/20 lobes) mice. Dots, 
individual lobes; red horizontal line, median. P values calculated using 1-way ANOVA with Tukey’s multiple-comparison test. (D) Violin plots quantifying 
the percentage of Ki67+ cells in lung tumors from mice of the indicated genotypes. K-RasG12D (4 mice/43 tumors), c-JunΔ/Δ; K-RasG12D (3 mice/54 tumors), 
Jnkk2-Jnk1; K-RasG12D (3 mice/29 tumors), and c-JunΔ/Δ; Jnkk2-Jnk1; K-RasG12D (4 mice/59 tumors). Each data point represents 1 tumor. Red horizontal line, 
median. P values calculated using 1-way ANOVA with Tukey’s multiple-comparison test. (E) c-Jun, phospho–c-JunSer73/phospho-JunDSer100, and JunD 
antibody stains of lung tumors from mice of the indicated genotypes. Scale bars: 50 μm, 5 μm (inset). (F) Schematic summary: JNK overexpression in the 
absence of c-Jun promotes oncogenic K-Ras–dependent tumorigenesis.
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Methods
Analysis of  public data from cancer genomics studies. Data from TCGA Research Network (TCGA Lung Adenocar-
cinoma), including mutations and putative copy number alterations, were analyzed using cBioportal software 
and visualized using the standard Oncoprint output. Patient prognoses was evaluated by Kaplan-Meier survival 
curves of LADC patients with low or high expression of JUN and JUND, with data from Kaplan–Meier plotter. 
Correlation analysis were performed using GEPIA (Gene expression profiling interactive analysis) software.
Mice. Nu/Nu mice were derived from the colony established by the Imperial Cancer Research Fund 
(ICRF nude). c-Junfl/fl (38), lsl-KRasG12D (5), p53fl/fl (39), c-JunAA (26), and JunDΔ/Δ (27) animals have been 
described before. Generation of  the lsl-Jnkk2-Jnk1 transgenic construct is described in Supplemental Fig-
ure 3. Constructs were electroporated into ES cells, stable transfectants were selected, and mice were gener-
ated by injection of  a positive ES cell clone into C57BL/6 blastocysts according to standard protocols (26).
Adenoviral infection. Adeno-CMV-Cre virus (Ad5CMVCre) was purchased from the Gene Transfer Vec-
tor Core, University of  Iowa (Iowa City, Iowa, USA). Intratracheal intubation was carried out on animals 
at 8–12 weeks of  age using a dose of  2.5 × 107 viral particles per mouse as described (25). Briefly, the ade-
novirus was prepared in PBS containing 10 μM calcium chloride and magnesium. Mice were anesthetized 
with isoflurane, and the virus preparation was administered via a catheter inserted into the trachea. Both 
male and female mice were used. A sample size of  at least 3 mice per genotype was used, with no sample 
exclusion criteria. Mice were culled 12 weeks after intubation for analysis. The effect size was not prespec-
ified. No animals were excluded from the analysis, and randomization was used.
S.c. graft tumors. Lung KP, JKP, and KPD tumor cells were resuspended as single-cell suspensions at 
1 × 105 cells/mL in PBS/Matrigel (Corning, 354230). In total, 100 μL (1 × 104 cells total) of  this sus-
pension was injected into opposite left (KP) and right (KPD) flanks of  athymic Nu/Nu nude mice. For 
survival curves, KP and JKP cells were injected in individual nude mice. Tumor grafts were measured 
with digital calipers, and tumor volumes were determined with the following formula: (length × width2) 
× (π/6). Tumor volumes are plotted as means ± SEM.
Orthotopic lung tumors. Lung KP and JKP tumor cells were resuspended as single-cell suspensions at 1 × 106 
cells/50 μL in PBS and delivered directly to the lungs of 8-week-old Nu/Nu by intratracheal intubation. Lungs 
were analyzed after 12 weeks after intubation.
Histological analysis. Animals were euthanized by cervical dislocation, and the lung and heart were pre-
pared for histopathological analysis as previously described (24). In short, excised lungs were incubated in 
ice-cold endotoxin-free PBS, then in 10% NBF overnight, and then in 70% industrial methylated spirit until 
further processing. Paraffin-embedded 4 μm sections were stained with the following antibodies: TTF-1 
(ab40880, Abcam), LacZ (AB9361, Abcam), c-Jun (610326, BD Biosciences), phospho–c-Jun Ser63 (9261, 
NEB), phospho–c-Jun Ser73 (9164, NEB), JunD (sc74, Santa Cruz Biotechnology Inc.), HMGA2 (8179, 
Cell Signaling Technology [CST]), and Ki67 (M7248, DAKO).
For quantification of  tumor burden, the area (μm2) of  existing individual tumors in each lobe was mea-
sured with QuPath software (40) (Measure > Show Annotation Measurements Tool) and represented as a 
percentage of  tumor area per lobe. The analysis was performed uniformity across all lung sections, and the 
whole lungs were used to derive data. For quantification of  cell proliferation, the number of  Ki67+ cells was 
automatically counted in individual tumors with QuPath software (Cell Analysis > Positive Cell Detection 
Tool) and represented as a percentage of  total cells in tumor area.
Isolation of  primary lung tumor cells. Primary murine LADC cells were obtained as previously described 
(41). Lung lobes were dissected out and immediately placed in 4 mL of  medium A (AdMEM/F12, B27, 
Figure 5. JunD is required for Ras-driven lung tumorigenesis. (A) Schematic representation of JunD–/–; lsl-KRasG12D mouse model. K-RasG12D expression 
was induced by intratracheal intubation (i.t.) with adenovirus carrying Cre recombinase (Adeno-Cre). LSL, stop cassette flanked by 2 loxP (locus of 
recombination) sites. (B) H&E and TTF-1 antibody stains of lung sections from mice of the indicated genotypes, 12 weeks after intubation. Scale bars: 2 
mm (whole sections), 50 μm (magnified areas). (C) Quantification of the tumor burden in whole lungs isolated from K-RasG12D (3 mice/15 lobes), JunD–/+; 
K-RasG12D (4 mice/20 lobes), and JunD–/–; K-RasG12D (3 mice/15 lobes) mice. Dots, individual lobes; red horizontal line, median. P values calculated using 
1-way ANOVA with Tukey’s multiple-comparison test. (D) Violin plots quantifying the percentage of Ki67+ cells in lung tumors from mice of the indicated 
genotypes. K-RasG12D (3 mice/35 tumors), JunD–/–; K-RasG12D (3 mice/67 untransformed lung regions). Each data point represents 1 untransformed area or 
tumor. Red horizontal line, median. P values calculated using unpaired t test with Welch’s correction. (E) c-Jun, phospho–c-JunSer63, phospho–c-JunSer73/
phospho-JunDSer100, JunD, and LacZ antibody stains of lung tumors from mice of the indicated genotypes. Scale bars: 50 μm, 5 μm (inset). (F) Graph 
showing the difference in cell proliferation between control (Scramble) and siJUND-transfected human NCI-H23 LADC cells. Graph indicates mean ± SEM. 
P values calculated using 1-way ANOVA with Tukey’s multiple-comparison test. (G) Impaired cell growth in siJUND-transfected NCI-H23 LADC cells is 
associated with apoptotic cell death based on the DEVD-NucView488 Caspase-3 dye that detects caspase-3 activity. Scale bars: 400 μm. 
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N2, 2% FCS, 1% penicillin/streptomycin, 10 μg/mL insulin, 20 ng/mL EGF, 20 ng/mL FGF, 100 μg/
mL Primocin) into GentleMACS C tubes and subjected to automated homogenization using GentleMACS 
dissociators at Tumor 2 mode, followed by addition of  300 U/mL collagenase IV (Worthington, LS004186) 
and hyaluronidase 300 U/mL (Worthington, LS002594), as well as incubation for 20 minutes at 37°C with 
constant shaking. Homogenized lungs were subjected to further dissociation at Tumor 3 mode, followed by 
centrifugation at 150g for 5 minutes at 4°C. The pellet was resuspended in medium A, and cells were plated 
onto Ultra-low attachment plates and placed in a humidified incubator at 37°C, 5% CO2. Ninety-six hours 
later, the medium was replaced with DMEM (10% FCS, 1% penicillin/streptomycin), and cells were replat-
ed on standard tissue culture plates. All cell lines were tested as mycoplasma negative by PCR assay.
Cell culture. Primary murine lung cells were maintained at 37°C with 5% CO2. We noticed that JKP cells 
maintained in culture for a prolonged period of time (passage > 15) lose their growth advantage over KP 
cells. Therefore, all experiments were performed using cells from passages 3–10. Where indicated, cells were 
treated with anisomycin (MilliporeSigma, A9789, final concentration 200 ng/mL) for 30 minutes to stimulate 
JNK-dependent phosphorylation of c-Jun/JunD, and/or with JNK inhibitor (Tocris Bioscience, Bio-Techne; 
SP600125; final concentration 20 μM) for 30 minutes before harvesting (after anisomycin stimulation, if  given).
Human LADC cell lines (NCI-H23, NCI-H441, NCI-H1792, and A549) were provided by the 
Francis Crick Institute Cell Services and cultured in RPMI-1640 medium supplemented with 10% 
FBS, 1% penicillin/streptomycin, and 2mM glutamine. All cells were tested Mycoplasma negative and 
maintained at 37°C with 5% CO2.
Immunoblotting. For protein analyses of  lung tumor cell lines, cells were harvested, washed in PBS, and 
resuspended in cell lysis buffer (9803, NEB) supplemented with protease inhibitor cocktail (MilliporeSigma). 
Protein amount was measured by Lowry assay. The following antibodies were used for Western blot analy-
ses: c-Jun (610326, BD Biosciences), phospho–c-Jun Ser63 (9261, New England Biolabs [NEB]), phospho–c-
Jun Ser73 (9164, NEB), JunD (sc74, Santa Cruz Biotechnology Inc.), JunD (5000, NEB), phospho–SAPK/
JNK Thr183/Tyr185 (4668 and 9251, NEB), SAPK/JNK (9252, NEB), phospho–p38 MAPK Thr180/
Tyr182 (9211, NEB), p38 MAPK (9212, NEB), tubulin (ab7291, Abcam), and β-actin (ab49900, Abcam). 
All primary antibodies were used at 1:1000 dilution. Horseradish peroxidase–conjugated (HRP-conjugated) 
secondary antibodies were used at 1:5000 dilution, and anti–β-actin HRP antibody was used at 1:30,000 
dilution. For Western blot utilizing the LI-COR system, DyLight goat anti–mouse 680 (5470, NEB) and 
DyLight goat anti–rabbit 800 (5151, NEB) secondary antibodies were used at 1:15,000 dilution. Separate 
immunoblots were used for each antibody.
Cell proliferation assay. Primary murine lung cells were seeded in 96-well plates at a density of  2 × 
103 cells per well. Twelve hours later, cells were treated with DMSO as vehicle, JNK inhibitor (Tocris 
Bioscience, Bio-Techne; SP600125, 20 μM), or p38 MAPK inhibitor (MilliporeSigma, SB203580, 10 μM) 
throughout the experiment. Cell confluence was measured over several days, using a hemocytometer. Alter-
natively, cell viability was measured as the intracellular ATP content using the CellTiter-Glo Luminescent 
Cell Viability Assay (Promega), following the manufacturer’s instructions.
JUND silencing and imaging apoptosis. Human LADC cell lines (NCI-H23, NCI-H441, NCI-H1792, 
and A549) were transfected with specific small interfering RNAs (siRNAs) against the JUND gene, using 
Lipofectamine RNAiMAX and 25 nM of  each siRNA according to the manufacturer’s instructions (Dhar-
macon) (42). Detection of  caspase-3 activity in cells was achieved through incubation with the cell-per-
meable caspase-3 substrate DEVD-NucView488 generated in-house by the Peptide Chemistry Laboratory 
as described (43). Forty-eight to 72 hours later, caspase-3 enzyme activity was detected using fluorescence 
microscopy, and cell number was counted using an automated cell counter.
Crispr/Cas9 deletion of  JunD. Guide RNA sequences targeting murine JunD were designed using the 
CHOPCHOP design tool (http://chopchop.cbu.uib.no). Two guide RNAs were designed with a spanning 
sequence of  200 bp. Guide RNA sequences were cloned into px458 and px459 (Addgene plasmids 48138 
and 48139, respectively). KP cells were transiently cotransfected with both guide RNAs, and 48 hours after 
transfection, cells were selected with 4 μg/mL puromycin for 72 hours. Single clones were then propagated 
in medium lacking puromycin and analyzed by immunoblot.
RNA-Seq/GSEA. KP and JKP cells were lysed with 600 μL 1% β-Mercaptoethanol in buffer RLT (QIA-
GEN). RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instruc-
tions. mRNA-Seq libraries were prepared using TruSeq RNA Library Preparation Kit v2 (Illumina) accord-
ing to the manufacturer’s instructions. Libraries were sequenced using the HiSeq2500 systems (Illumina). 
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Sequenced reads were mapped and quantified to mm10 whole genome and refseq transcript RSEM v1.2.11 
(including Bowtie v2.1.0) with parameters --bowtie2-sensitivity-level very_sensitive --estimate-rspd. RNA-Seq 
data were deposited in the Gene Expression Omnibus repository under accession number GSE87387.
GSEA was performed on the transcription profile of  KP and JKP cells with the software GSEA v4.0.3. 
The settings in analyses were: number of  permutations = 1000, permutation type = gene set. The following 
gene set databases were used: Hallmarks and Biocarta.
Human study approval and lung tumor analysis. Human biological samples were collected, stored, and 
managed by the Cordoba node belonging to the Biobank of  the Andalusian Health Service (Servi-
cio Andaluz de Salud — SAS) and approved by the Ethics and Clinical Research Committee of  the 
University Hospital Reina Sofia. All subjects gave informed consent. Pathologists assessed all samples 
before use. mRNA extracted from the samples was analyzed by quantitative PCR. The primers were 
as follows: Actin forward, 5′-GAAAATCTGGCACCACACCT-3′, and reverse, 5′-TAGCACAGCCT-
GGATAGCAA-3′; JUN forward, 5′-CCAAAGGATAGT GCGATGTTT-3′, and reverse, 5′-CTGTC-
CCTCTCCACTGCAAC-3′; JUND forward, 5′-CAGCGAGGAGCAGGAGTT-3′, and reverse, 
5′-GAGCTGGTTCTGCTTGTGTAAAT-3′.
Statistics. To analyze tumor area and tumor cell proliferation, a 2-tailed Welch’s t test was used to com-
pare data from 2 different genotypes. This test does not assume equal variances and performs better when 
sample sizes are unequal. One-way or 2-way ANOVA was used to compare data from 3 or more different 
groups. Data distribution was not formally analyzed. Estimates of  variation (range, SD, or SEM as speci-
fied in the figure legends) are given in the figures. A P value less than 0.05 was considered significant.
Study approval. All animal experiments were approved by the Francis Crick Institute Animal Ethics 
Committee and conformed to UK Home Office regulations under the Animals (Scientific Procedures) Act 
1986 including Amendment Regulations 2012. Human biological samples were collected, stored, and man-
aged by the Cordoba node belonging to the Biobank of  the Andalusian Health Service (Servicio Andaluz 
de Salud — SAS) and approved by the Ethics and Clinical Research Committee of  the University Hospital 
Reina Sofia. All subjects gave informed consent.
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